

BioLife Solutions to Attend and Present at Upcoming Investor & Scientific Conferences

BOTHELL, Wash., Jan. 16, 2018 /PRNewswire/ -- [BioLife Solutions](#), Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue [hypothermic storage](#) and [cryopreservation freeze](#) media, today announced that CEO Mike Rice and CFO Roderick de Greef will be attending and presenting at the following investor conferences:

- BIO CEO & Investor Conference; February 12th – 13th; New York Marriott Marquis Hotel; <https://www.bio.org/events/bio-ceo-investor-conference>
- B Riley FBR Inaugural China Healthcare Investment & Partnering Symposium (CHIPS); March 15th – 17th; InterContinental Hotel Hangzhou, China; https://brcfbr.meetmax.com/sched/event_47969/~public/conference_home.html?event_id=47969

BioLife Solutions will also be attending and/or exhibiting at the following scientific conferences:

- Phacilitate Cell & Gene Therapy World 2018 conference; January 22nd – 25th; Hyatt Regency Miami; <http://www.cellandgenetherapyworld.com>
- The 2018 World Stem Cell Summit; January 22nd – 26th; Hyatt Regency Miami; <http://www.worldstemcellsummit.com>
- 4th Annual Perinatal Stem Cell Congress; March 1st – 2nd; The Leonardo Museum; Salt Lake City, UT <https://www.perinatalstemcells.com/2018-conference-agenda.html>
- Parenteral Drug Association 2018 Annual Meeting; March 19th – 21st; Loews Sapphire Falls; Orlando, FL; <https://www.pda.org/global-event-calendar/event-detail/2018-pda-annual-meeting>
- Optimization of Cell and Gene Therapy Production, March 26th – 27th; The Ritz-Carlton; Washington DC; <http://www.cbinet.com/conference/pc18455>

About BioLife Solutions

BioLife Solutions is the leading developer, manufacturer and supplier of proprietary clinical grade cell and tissue [hypothermic storage](#) and [cryopreservation freeze](#) media for cells and tissues. Our proprietary HypoThermosol[®] and CryoStor[®] platform of solutions are highly valued in the regenerative medicine, biobanking and drug discovery markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function.

For more information please visit www.biolifesolutions.com, and follow BioLife on [Twitter](#).

Media & Investor Relations

Roderick de Greef
Chief Financial Officer
(425) 686-6002
rdegreef@biolifesolutions.com

SOURCE BioLife Solutions, Inc.

Additional assets available online:

<https://investors.biolifesolutions.com/2018-01-16-BioLife-Solutions-to-Attend-and-Present-at-Upcoming-Investor-Scientific-Conferences>